Contrary to conventional wisdom, Netflix actually stands to benefit greatly from the AT&T-Time Warner merger. Here’s why:
Largely unknown to most investors, mega mergers with antitrust implications often require the approval not just of regulators, but of competitors across the industry landscape as well. Put simply, if AT&T and Time Warner’s biggest competitors give their OK, then regulators are much more likely to allow a deal to pass.
Those testimonials from the competition don’t come cheaply, however. Companies will often ask for big favors in exchange for their support of large mergers. And that’s great news for Netflix. In Bloomberg, Craig Moffett, an analyst at MoffettNathanson LLC, said,
The part you never see is what the various players demand behind the scenes in order to support the deal in Washington…You’ll have all kinds of programmers essentially demanding a pound of flesh. It’s a gravy train for everybody.
Netflix, for better or worse, will end up speaking on behalf of an entire class of would-be competitors…That gives them tremendous negotiating leverage for their support of the deal.
The company’s influence can be huge. Netflix opposed Comcast’s proposal to buy Time Warner Cable in 2014, and regulators wound up blocking the deal. Later, TWC was purchased by Charter Communications instead, a deal that Netflix supported — likely in exchange for some form of preferential treatment.
Full Content: Investing
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas